Dr. Wu Nanhai serves as Deputy Director of the Hematology and Oncology Center, Director of Ward 9, and Associate Chief Physician at Beijing Jingdu Children's Hospital, a leading institution in China's pediatric hematology and oncology field. With nearly 40 years of clinical and academic leadership experience, he has become a key figure in advancing the treatment of refractory leukemia, relapsed leukemia, and infant leukemia, achieving breakthrough therapeutic outcomes aligned with international standards.
Dr. Wu's career began at the Sixth Medical Center of the Chinese People's Liberation Army General Hospital (formerly the Navy General Hospital), where he served as Deputy Director of Pediatrics. His early work in the 1990s laid the foundation for modern pediatric leukemia treatment protocols in China. In 2019, he joined Beijing Jingdu Children's Hospital and led the Hematology and Oncology Department to become a national diagnosis and treatment center for high-risk leukemia cases. Under his leadership, the remission rate for refractory and relapsed leukemia cases has reached over 90%, with a long-term survival rate approaching 70%; the long-term survival rate for infant leukemia exceeds 65%.
Under his leadership, the hospital took the lead in China in carrying out transplantation treatments for pediatric myelodysplastic syndrome (MDS), pediatric hemophagocytic syndrome, EB virus-related lymphoproliferative diseases, and severe congenital neutropenia (SCN).
Dr. Wu's professional field covers the diagnosis, chemotherapy, and transplantation treatment of high-risk pediatric hematological malignancies.
Leukemia Subtypes:
1. Refractory/Relapsed Acute Lymphoblastic Leukemia (ALL): Salvage therapies integrating chemotherapy, molecular targeted therapy, CAR-T therapy, and blinatumomab.
2. Infant Leukemia (<1 year old): Modified chemotherapy protocols to improve survival rates and reduce chemotherapy-related toxicity and relapse risk.
Deputy Director of the Hematology and Oncology Center, Director of Ward 9, and Associate Chief Physician at Beijing Jingdu Children's Hospital (current position)
Member of the Pediatric Hematology Group of the Chinese Medical Association
Member of the Child and Adolescent Lymphoma Special Committee of the Chinese Society of Clinical Oncology (CSCO)
Member of the Blood/Oncology Alliance of the National Children's Medical Center
Member of the Children's Oncology Professional Committee of the Chinese Research Hospital Association
Expert in the Beijing Municipal Medical and Health Science and Technology Innovation Achievement Transformation Expert Database
Deputy Director of the Changping District Pediatric Quality Control Center, Beijing
Executive Deputy Editor-in-Chief of Chinese Journal of Pediatric Blood and Oncology
Studied under Professor Lü Shangen, a pioneer in pediatric hematology at the PLA 301 Hospital, with research focusing on the pathogenesis of leukemia and treatment optimization.
Advanced studies in childhood leukemia chemotherapy at Beijing Children's Hospital; advanced studies in hematopoietic stem cell transplantation (HSCT) at the Third Medical Center of the PLA General Hospital (formerly PLA 307 Hospital).
Treatment of relapsed/refractory childhood leukemia
Treatment of infant leukemia
Chinese (Mandarin)
1. Published more than 50 papers in domestic and international academic journals, including 3 SCI papers.
2. Awarded 1 Second Prize of the Ministry of Education Science and Technology Progress Award, 1 Third Prize of the Military Science and Technology Progress Award, 3 Third Prizes of the Military Medical Achievement Award, and 1 Third Prize of the China Refrigeration Society Science and Technology Progress Award.
3. Edited or co-edited 4 books.
Overall rating of 4.9/5 (based on over 150 verified reviews)
1. "Dr. Wu never gave up on my daughter's relapsed leukemia. His innovative treatment saved her life." (2024 review)
2. "He patiently explained every step of the treatment and treated us like family." (2023 review)
3. 92% of families praised his accessibility through 24-hour remote medical consultations.
4. 88% of families reported "clearly understanding treatment risks and benefits."
Through clinical innovation, talent cultivation, and patient rights advocacy, Dr. Wu Nanhai has redefined the field of pediatric hematology in China. His pioneering work in refractory leukemia and infant-specific treatment protocols has positioned Beijing Jingdu Children's Hospital as a significant global player in pediatric oncology treatment. Looking to the future, he is committed to integrating AI-driven precision medicine and expanding access to advanced treatments in rural areas.
EN
CN
